Judy Gordon, DVM
Company Advisor, Clinical and Regulatory Affairs
Dr. Judy Gordon has over 25 years of ophthalmic industry experience and is arguably the country’s leading clinical and regulatory affairs specialist in ophthalmic medical devices. Early on in her career, Dr. Gordon was with Chiron Vision, a division of Chiron Corporation, from the company’s founding in 1986 through its acquisition by Bausch & Lomb in 1997.
+ READ MORE
At Chiron Vision, Dr. Gordon served as Sr. Vice President of Research and Development and as Vice President of Scientific Affairs, with responsibility for product development, clinical research, regulatory affairs, and regulatory compliance.
Dr. Gordon has been involved in the product development, clinical, and regulatory activities for a broad range of products including glaucoma instruments; glaucoma implants; dry eye devices; conventional, accommodating and phakic IOLs; excimer and femtosecond lasers; intravitreal drug delivery systems for the treatment of CMV retinitis, macular degeneration, diabetic retinopathy, and BRVO/CRVO; and other novel drugs and devices.
Dr. Gordon has taken multiple 510Ks, PMAs and NDAs through the FDA review process, and has directed large-scale clinical trials of medical devices, biologics, and pharmaceutical products. In total, Dr. Gordon has prepared all or part of over 100 successful 510Ks, 20 successful PMA applications, and 3 NDA applications. She served as the industry representative to the Ophthalmic Devices Advisory Panel and to the Dispute Resolution Advisory Panel of the Center for Devices and Radiologic Health (CDRH).
Company Advisor, Intellectual Property
Dr Mika Mayer is a Partner at Cooley LLP and is one of the most sought-after patent lawyers in the medical device, drug delivery, and pharmaceutical fields. Mika develops IP strategies and prosecutes patent applications with a laser focus on protecting her clients’ interests and maximizing their value and commercial success.
+ READ MORE
In addition to patent portfolio development and prosecution, Mika has led more than 400 IP due diligence reviews for some of the most sophisticated global health care companies and investors. She is consistently called upon by top decision makers in the medical device community for her ability to translate IP risks into business risks, and provide strategic guidance and oversight in this regard. As these industries have gone global, so has her practice, with medical device companies around the world utilizing her expertise.
Mika was named, “Patent Prosecution Attorney of the Year: Medical Devices” by LMG Life Sciences 2013. In 2014, she was recognized by the Daily Journal as one of the Top 25 IP Portfolio Managers in California.
She is a guest lecturer for Stanford’s Biodesign Innovation Class, a current member of the Science Accelerator Committee of the American Heart Association, and a board member of the Women in Law Empowerment Forum.
Company Advisor, Corporate Counsel
Stephen Thau is a Partner at Morrison & Foerster and has been recognized as one of the top biotech attorneys in California. His practice focuses on the representation of life sciences and medical device companies in transactional matters, including merger and acquisition, licensing and collaborations, strategic alliances, public offerings, and equity and debt financings.
+ READ MORE
He has represented companies in numerous public offerings, public and private M&A transactions, and collaboration agreements, and companies and investors in over 100 venture capital and debt financing transactions.
Stephen is a member of the Board of BayBio, Northern California’s leading life science association. He re-joined Morrison & Foerster in 2008 after having practiced corporate law for ten years at Venture Law Group and Heller Ehrman LLP.
Stephen graduated Order of the Coif from Stanford Law School, where he was managing editor of the Stanford Law Review, and graduated magna cum laude from Harvard College in Biology.